[Effects of Paclitaxel and Quizartinib Alone and in Combination on AML Cell Line MV4-11 and Its STAT5 Signal Pathway].

Objective: To investigate the effects of paclitaxel, quizartinib and their combination on proliferation, apoptosis and FLT3/STAT5 pathway of human leukemia cell line MV4-11 (FLT3-ITD+).

Methods: MV4-11 cells were treated with paclitaxel and quizartinib at different concentrations for 24 h, 48 h and 72 h, respectively, and then the two drugs were combined at 48 h to compare the inhibition of proliferation, the apoptosis rate was detected by flow cytometry, the expression of FLT3 and STAT5 mRNA was determined by fluorescence quantitative PCR, and the protein expression of FLT3, p-FLT3, STAT5 and p-STAT5 was determined by Western blot.

Results: Different combination groups of paclitaxel and quizartinib had synergistic inhibitory effect.

[Exploring the Mechanism of Paclitaxel Inhibiting T-cell Lymphoma based on High-throughput Sequencing and Public Databases].

Objective: To analyze gene expression profile of T cell lymphoma Jurkat cell line treated with paclitaxel by computational biology based on next generation sequencing and to explore the possible molecular mechanism of paclitaxel resistance to T cell lymphoma at gene level.

Methods: IC50 of paclitaxel on Jurkat cell line was determined by CCK-8 assay. Gene expression profile of Jurkat cells treated with paclitaxel was acquired by next generation sequencing technology.

[Effect of Mangiferin on Proliferation of FLT3-ITD Mutation Positive Acute Myeloid Leukemia Cell MV4-11 and Its Mechanism].

Objective: To investigate the effects of mangiferin on proliferation, apoptosis and cycle of FLT3-ITD mutation-positive acute myeloid leukemia cells and its mechanism.

Methods: The effects of different concentration of mangiferin on proliferation of MV4-11 cells were detected by CCK8 method. Apoptosis, cell cycle and FLT3 transmembrane protein expression were detected by flow cytometry.

[Changes of serum anti-schistosome antibody levels in schistosomiasis japonica patients after treatment].

Objective: To investigate the changes of serum anti-schistosome antibody titers in schistosomiasis japonica patients after treatment, in order to provide the evidence for formulating the schistosomiasis surveillance program in marshland and lake regions.

Methods: Upon prospective cohort study, the stool examination positive schistosomiasis patients and blood examination positive suspected patients (the titer was more than 1:80, including 1:80) were selected as the research objects in Jiangling County in 2014, and they received the 2-day praziquantel therapy. Half year, one year and two years after the treatment, their blood samples and fecal samples were collected for IHA anti-schistosome antibody detections and schistosome egg and miracidium detections.

Complete mitochondrial genome of the Xiangjiang barbel chub Squaliobarbus curriculus: comparative analysis of the genetic variation associated with geographical population.

The barbel chub (Squaliobarbus curriculus), a kind of small commercial fish, is widespread in China. In this study, we sequenced the mitochondrial genome of the barbel chub from the Xiangjiang River. The total length of the mitochondrial genome is 16,619 bp, with the base composition of 31.

[Effects of mangiferin on cell cycle status and CDC2/Cyclin B1 expression of HL-60 cells].

Objective: To study the effects of mangiferin on cell cycle status and CDC2/Cyclin B1 expression in HL-60 cells, and its molecular mechanism for treating leukemia.

Methods: The effect of Mangiferin on HL-60 cells proliferation was determined by MTT assay; The change of cell cycle status in HL-60 cells treated with mangiferin was performed by the flow cytometry; The expressions of CDC2 mRNA and Cyclin B1 mRNA were detected by semiquantitative RT-PCR.

Results: The growth inhibition effects of mangiferin in HL-60 cells were enhanced as the mangiferin concentration increased and exposure time prolonged; HL-60 cells in G2/M phase increased in a dose-dependent way 24 hours after mangiferin administration, indicating G2/M phase blockage; the expressions of CDC2 mRNA and Cyclin B1 mRNA enhanced in a dose-dependent way and came to the peak at 80 micromol/L mangiferin.